IGMS earnings

– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct

– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway extended into 2027 – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in the development

– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial – MOUNTAIN VIEW, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) --  IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended June 30, 2024 and provided an update on recent developments. "We continue to make significant progress in the clinical

- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments. "We are pleased to have exceeded our enrollment target of 110 patients in our randomized study of 3 mg/kg of aplitabart plus FOLFIRI and bevacizumab in second line colorectal cancer," said Fred Schwa

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments. "We made significant progress during 2023 in the clinical development of our two lead product candidates in therapeutic areas that we believe have the greatest potential to produce significant near-term value," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "Enrollment in our randomized clinical trial of aplitabart plus FOLFIRI and bevacizumab in

– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023. "During the third quarter, we continued to execute across our clinical development pipeline," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "We have significantly expanded the number of active sites for our aplitabart randomized study, including multiple international s

  – Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – – Progression-free survival of 5.6 months in median third-line colorectal cancer patients without bevacizumab – – Promising safety profile in combination with FOLFIRI and bevacizumab – – Randomized combination trial in second-line colorectal cancer patients initiated in Q1 2023 – MOUNTAIN VIEW, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced an update on its clinical development program for IGM-

– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that it will host a conference call and live webcast to provide an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, on Friday, June 2, 2023 at 7:00 p.m. ET. The Company will be providing a clinical data update on 3 mg/kg IGM-8444 + FOLFIRI (± bevacizumab) in median third line metastatic colorectal cancer patients from a non-randomized clinical trial cohort. The event will feature

– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab, in the middle of 2023 – – Plans to begin clinical testing of imvotamab in severe systemic lupus erythematosus and severe rheumatoid arthritis – MOUNTAIN VIEW, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on

– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial – – Imvotamab to move forward into clinical studies in multiple autoimmune diseases – – Initiation of Phase 1 clinical trial for targeted immunostimulatory IL-15 cytokine IGM-7354 in patients with solid tumors – –   Company to hold conference call and webcast today at 4:30 p.m. EDT –   MOUNTAIN VIEW, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 20

MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 30, 2023. In connection with the earnings release, IGM's management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, March 30, 2023, to discuss the Company's financial results and provide a corporate update. The webcast can be accessed by clicking the link: https://edge.media-server.com/mmc/p/ud83kix8 and will be available on the "Events and Presentations" p

– Data from T cell Engager Portfolio for Hematologic Malignancies, Including First Preclinical Data for IGM-2644 and IGM-2537, Selected for Poster Presentations at 2022 ASH Annual Meeting – – Data Update from Phase 1 Trial of Imvotamab Demonstrates Durable Benefit for R/R NHL Patients, with 7/8 Complete Response Patients Tumor Free After 1 Year – MOUNTAIN VIEW, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent developments. "We have made substantial prog

– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 – – Received $150 Million Upfront Payment in Connection with Closing of Collaboration Agreement with Sanofi – MOUNTAIN VIEW, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent developments. "We continued to make good progress in the second quarter in our two Phase 2 clinical trials of our IgM T cell bispecific antibody, imvotamab, and in our Phase 1 clinical trial of our IgM

– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate Development, Regulatory and Commercial Milestones – – Ongoing Progress in Clinical Programs with Two Phase 2 Studies of Two Doses of IGM-2323, 100 mg and 300 mg, in Patients with DLBCL and FL Initiated – – Company to Host Conference Call and Webcast Today at 8:00 a.m. EST – MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its fin

MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast today, Tuesday, March 29, 2022, at 8:00 am ET to discuss the Company's global collaboration agreement with Sanofi, as recently announced. The conference call may be accessed by dialing (866) 649-1996 (domestic) or (409) 217-8769 (international) and referring to conference ID 4983742. A live webcast of the presentation will be available on the "Events and Presentations" page in the "Investors" section of the Comp

- Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and FL, and has a Favorable Safety Profile - - Phase 2 Clinical Trials in DLBCL and FL and Combination Clinical Trials to be Initiated -   - Company to Host Conference Call and Webcast Today at 7:30 p.m. EST - MOUNTAIN VIEW, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the presentation of clinical results from the Company's Phase 1 trial evaluating IGM-2323, a novel bispecific IgM a

MOUNTAIN VIEW, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 11, 2021, at 7:30 p.m. EST. The event will take place following an oral presentation featuring clinical data from the Phase 1 dose escalation study evaluating IGM-2323, the Company's novel CD20 x CD3 T cell engager IgM antibody for the treatment of B cell proliferative diseases, at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. IGM's management team will be joined

– Plans to Initiate Phase 2 Studies of IGM-2323 in Diffuse Large B-cell Lymphoma and Follicular Lymphoma – – Data from IGM-2323 Selected for Oral Presentation at 2021 ASH Annual Meeting – – IGM-8444 Successfully Completes Phase 1 Monotherapy Dose Escalation – – IGM-8444 Showed No Clinically Significant Liver Toxicity or Dose Limiting Toxicities Observed to Date – – IGM-2644 (CD38 x CD3) Expected to Enter Clinical Testing for Multiple Myeloma in 2022 – – IGM Establishes Infectious Diseases and Autoimmunity and Inflammation Business Units – MOUNTAIN VIEW, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on cre

STOCKHOLM, Sept. 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed dose escalation section of the phase 1b study with MIV-818, presented today at the European Society for Medical Oncology (ESMO) congress. The conference call will be held today, September 16, at 15:00 CET, to update on the study and the plan for the MIV-818 program. Medivir's lead candidate drug MIV-818 has the potential to become a liver-targeted, orally administered drug that can help patients with liver cancer. In April, it was announced that the overall results from the first part of the phase 1b study with MIV-818 were positive wit

STOCKHOLM, Sept. 13, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled "Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)" has been released on the European Society for Medical Oncology (ESMO) website (https://www.esmo.org/meetings/esmo-congress-2021). The results from the completed phase 1b monotherapy dose escalation part of the study will be presented by Dr Debashis Sarker, King´s College, London, as an e-poster (number 527P) at ESMO on Thursday September 16. Medivir will host a conference call to update on the progress and plans for t

– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – Expansion of IgM Platform into Infectious Diseases – MOUNTAIN VIEW, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent developments. "We continue to make steady progress in the development of our innovative product pipeline, including the successful completion of the initial dose escalation portion of our IG

– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – IND Filing for IGM-7354 Planned in 2021 – MOUNTAIN VIEW, Calif., May 06, 2021 (GLOBE NEWSWIRE) --  IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent developments. "We are very pleased with the progress we made in the first quarter towards achieving our clinical and pipeline goals for 2021," said Fred Schwarzer, Chief Executive Officer of IGM Biosci